The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Evaluation of the impact of polyclonal infection and heteroresistance on treatment of tuberculosis patients
Open accessAbstract
Mixed strain infections of Mycobacterium tuberculosis make diagnosis, treatment, and control of tuberculosis (TB) more difficult. This study was aimed to evaluate the relationship between mixed infections, antibiotic resistance patterns and treatment of TB patients. In this study, among 2850 suspected TB clinical samples, a total of ninety-six clinical samples from 66 TB confirmed patients were subjected to the 24-locus variable-number tandem repeat method to evaluate the prevalence of mixed infections. For all studied strains, 288 colonies (three individual clones for each sample) were isolated from different colonies and separately analyzed by the Drug Susceptibility Test (DST). For all patients, follow up was done after 6 months of treatment. Based on direct 24 loci MIRU-VNTR, in the 66 TB patients, 53% (35/66) showed mixed infection. In the mixed samples, 45.71% (16/35) showed different antibiotic resistant patterns. Among the mixed infection patients, eight (22.9%; 8/35) showed treatment failure after six- month therapy. Six of these non-treated patients (75%; 6/8) had different antibiotic resistant patterns. We conclude that mixed infections, have a negative impact on treatment of TB patients especially when co-infecting M. tuberculosis strains display heteroresistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For diagnosed fungal infections, it may lead to persistent infections that require longer or more aggressive treatment regimens [27,28,29,30].”
From Insight into the Mechanisms and Clinical Relevance of Antifungal Heteroresistance (2025) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Supply, P., Allix, C., Lesjean, S., Cardoso-Oelemann, M., Rüsch-Gerdes, S., Willery, E., Savine, E., de Haas, P., van Deutekom, H., Roring, S., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01392-06 · Cited by 1,274
Bacteremia causes hippocampal apoptosis in experimental pneumococcal meningitis
Østergaard, C., Leib, S. L., Rowland, I., & Brandt, C. T. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-1 · Cited by 228
Cohen, T., van Helden, P. D., Wilson, D., Colijn, C., McLaughlin, M. M., Abubakar, I., & Warren, R. M. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00021-12 · Cited by 193
Zetola, N. M., Shin, S. S., Tumedi, K. A., Moeti, K., Ncube, R. T., Nicol, M. P., Collman, R. G., Klausner, J. D., & Modongo, C. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02489-13 · Cited by 142
Hofmann-Thiel, S., van Ingen, J., Feldmann, K., Turaev, L., Uzakova, G., Murmusaeva, G., van Soolingen, D., & Hoffmann, H. (2008) · European Respiratory Journal · doi:10.1183/09031936.00089808 · Cited by 132
Merker, M., Kohl, T. A., Roetzer, A., Trübe, L., Richter, E., Rüsch–Gerdes, S., Fattorini, L., Oggioni, M. R., Cox, H. S., Varaine, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082551 · Cited by 130
Cohen, T., Wilson, D., Wallengren, K., Samuel, E. Y., & Murray, M. B. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.01378-10 · Cited by 77
Kumar, P., Balooni, V., Sharma, B., Kapil, V., Sachdeva, K. S., & Singh, S. (2013) · Tuberculosis · doi:10.1016/j.tube.2013.10.001 · Cited by 65
Zetola, N. M., Modongo, C., Moonan, P. K., Ncube, R. T., Matlhagela, K., Sepako, E., Collman, R. G., & Bisson, G. P. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu040 · Cited by 56
Diversity of Mycobacterium tuberculosis genotypes circulating in Ndola, Zambia
Mulenga, C., Shamputa, I. C., Mwakazanga, D. K., Kapata, N., Portaels, F., & Rigouts, L. (2010) · BMC Infectious Diseases · doi:10.1186/1471-2334-10-177 · Cited by 52
Cited by
Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management
Liebenberg, D., Gordhan, B. G., & Kana, B. D. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.943545 · Cited by 184
Cao, Y., Parmar, H., Gaur, R. L., Lieu, D., Raghunath, S., Via, N., Battaglia, S., Cirillo, D. M., Denkinger, C. M., Georghiou, S. B., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02314-20 · Cited by 108
Relapse, re-infection and mixed infections in tuberculosis disease
McIvor, A., KOORNHOF, H. J., & Kana, B. D. (2017) · Pathogens and Disease · doi:10.1093/femspd/ftx020 · Cited by 107
Dookie, N., Ngema, S. L., Perumal, R., Naicker, N., Padayatchi, N., & Naidoo, K. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00180-19 · Cited by 106
Dookie, N., Khan, A., Padayatchi, N., & Naidoo, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.775030 · Cited by 72
Metadata
- Authors
- Kargarpour Kamakoli, M., Sadegh, H. R., Farmanfarmaei, G., Masoumi, M., Fateh, A., Javadi, G., Rahimi Jamnani, F., Vaziri, F., & Siadat, S. D.
- Affiliations
- Islamic Azad University, Tehran (IR)
- Pasteur Institute of Iran (IR)
- Corresponding author
- Vaziri, Farzam
- ORCID
- Venue
- Scientific Reports
- Published
- 2017-01-25
- Volume
- 7
- Issue
- 1
- Pages
- 41410-41410
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5264600
- OpenAlex
- W2581459208
- Cited by
- 51
- References
- 21
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 2 · 2020: 8 · 2019: 4 · 2018: 6 · 2017: 4
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pasteur Institute of Iran
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- tuberculosis, Mycobacterium tuberculosis, co-infection, polyclonal infection, heteroresistance, antibiotic resistance, treatment failure, MIRU-VNTR, strain typing, drug susceptibility testing
- MeSH terms
- Follow-Up Studies, Humans, Mycobacterium tuberculosis, Tuberculosis, Multidrug-Resistant, Minisatellite Repeats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of the impact of polyclonal infection and heteroresistance on treatment of tuberculosis patients. https://app.cochat.ai/papers/10.1038/srep41410
- The paper
- Kargarpour Kamakoli, M., Sadegh, H. R., Farmanfarmaei, G., Masoumi, M., Fateh, A., Javadi, G., Rahimi Jamnani, F., Vaziri, F., & Siadat, S. D. (2017). Evaluation of the impact of polyclonal infection and heteroresistance on treatment of tuberculosis patients. Scientific Reports. https://doi.org/10.1038/srep41410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
